NCT06355037 - Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 20, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

January 31, 2025

Conditions

Triple-negative Breast Cancer

Interventions

DRUG

Quercetin

quercetin 1000mg d1-d3, qw

DRUG

Dasatinib

Dasatinib 50mg d1-d3, qw

DRUG

Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum

Trial Locations (1)

RECRUITING

270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER